drugset / Trial / NCT04521569
Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System
Phase 0
Completed
47 enrolled
University of Maryland, Baltimore
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.
Timeline
- Start
- 2020-06-22
- Primary completion
- 2024-06-23
- Completion
- 2024-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regadenoson | Diagnostic / imaging agent | 1.44 ug/kg | Other |
Indications
No indication recorded.